Raphael Pharmaceutical Inc. (RAPH) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US27785B2088
Raphael Pharmaceutical Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -1.25 m USD |
| EBIT | -1.28 m USD |
| Net income | -1.28 m USD |
| Diluted EPS – continuing operations | 0.07 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Raphael Pharmaceutical Inc.
Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune diseases. Raphael Pharmaceutical Inc., is headquartered in Jaffa, Israel.
More stocks
- GAIA, INC (GAIA)
- NORTECH SYSTEMS INC (NSYS)
- Birchtech Corp. (BCHT)
- Latch, Inc. (LTCH)
- WeShop Holdings Limited Class A Ordinary Shares (WSHP)
- KOSS CORP (KOSS)
- Black Hawk Acquisition Corp (BKHA)
- PARKS AMERICA, INC (PRKA)
- Creatd, Inc. (CRTD)
- FORUM MARKETS Inc (FRMM)
- Western Alaska Minerals Corp (WAM.V)
- InspireMD, Inc. (NSPR)
Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.